AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 223 filers reported holding AMICUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,488,058 | -6.9% | 7,523,689 | -3.8% | 0.02% | -5.3% |
| Q2 2023 | $98,222,918 | +17.9% | 7,820,296 | +4.1% | 0.02% | +11.8% |
| Q1 2023 | $83,341,805 | -15.8% | 7,515,041 | -7.3% | 0.02% | -15.0% |
| Q4 2022 | $98,990,706 | +17.7% | 8,107,347 | +0.6% | 0.02% | +11.1% |
| Q3 2022 | $84,109,000 | -29.0% | 8,056,375 | -26.9% | 0.02% | -25.0% |
| Q2 2022 | $118,405,000 | -53.0% | 11,024,744 | -58.6% | 0.02% | -44.2% |
| Q1 2022 | $252,083,000 | -18.1% | 26,619,107 | -0.1% | 0.04% | -12.2% |
| Q4 2021 | $307,792,000 | +32.7% | 26,648,674 | +9.7% | 0.05% | +25.6% |
| Q3 2021 | $232,024,000 | +53.6% | 24,295,698 | +55.0% | 0.04% | +56.0% |
| Q2 2021 | $151,074,000 | +8.4% | 15,671,449 | +11.1% | 0.02% | 0.0% |
| Q1 2021 | $139,386,000 | -40.4% | 14,107,972 | +39.2% | 0.02% | -41.9% |
| Q4 2020 | $234,052,000 | +176.1% | 10,136,467 | +68.9% | 0.04% | +138.9% |
| Q3 2020 | $84,764,000 | -16.4% | 6,003,155 | -10.7% | 0.02% | -21.7% |
| Q2 2020 | $101,387,000 | +134.4% | 6,723,291 | +43.6% | 0.02% | +109.1% |
| Q1 2020 | $43,254,000 | -11.7% | 4,681,177 | -6.9% | 0.01% | +10.0% |
| Q4 2019 | $48,977,000 | -21.2% | 5,028,341 | -35.1% | 0.01% | -28.6% |
| Q3 2019 | $62,144,000 | -40.1% | 7,748,814 | -6.7% | 0.01% | -39.1% |
| Q2 2019 | $103,693,000 | -1.2% | 8,308,724 | +7.7% | 0.02% | -4.2% |
| Q1 2019 | $104,906,000 | +44.6% | 7,713,651 | +1.9% | 0.02% | +33.3% |
| Q4 2018 | $72,540,000 | -14.3% | 7,571,962 | +8.1% | 0.02% | 0.0% |
| Q3 2018 | $84,648,000 | -33.1% | 7,001,370 | -13.5% | 0.02% | -35.7% |
| Q2 2018 | $126,465,000 | +2.0% | 8,096,364 | -1.8% | 0.03% | 0.0% |
| Q1 2018 | $123,995,000 | +55.7% | 8,244,333 | +49.0% | 0.03% | +55.6% |
| Q4 2017 | $79,621,000 | -12.9% | 5,533,131 | -8.7% | 0.02% | -14.3% |
| Q3 2017 | $91,411,000 | +51.5% | 6,061,734 | +1.2% | 0.02% | +50.0% |
| Q2 2017 | $60,327,000 | +58.4% | 5,990,808 | +12.2% | 0.01% | +55.6% |
| Q1 2017 | $38,083,000 | +557.6% | 5,341,132 | +358.4% | 0.01% | +800.0% |
| Q4 2016 | $5,791,000 | -29.1% | 1,165,137 | +5.5% | 0.00% | -50.0% |
| Q3 2016 | $8,170,000 | +37.4% | 1,104,117 | +1.4% | 0.00% | 0.0% |
| Q2 2016 | $5,946,000 | -32.3% | 1,089,017 | +4.8% | 0.00% | 0.0% |
| Q1 2016 | $8,778,000 | -13.0% | 1,038,773 | -0.1% | 0.00% | -33.3% |
| Q4 2015 | $10,084,000 | -27.8% | 1,039,603 | +4.1% | 0.00% | -25.0% |
| Q3 2015 | $13,971,000 | -0.1% | 998,611 | +1.1% | 0.00% | 0.0% |
| Q2 2015 | $13,983,000 | +321.9% | 988,200 | -30.5% | 0.00% | +300.0% |
| Q2 2013 | $3,314,000 | – | 1,422,696 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |